European confidence and optimism in biotechnology is increasing, according to a survey conducted by the European Commission (EC), with particular support being seen in the area of regenerative medicines, including stem cell research and embryonic stem cell research.
European confidence and optimism in biotechnology is increasing, according to a survey conducted by the European Commission (EC), with particular support being seen in the area of regenerative medicines, including stem cell research and embryonic stem cell research.
According to the EC, biotechnology is a major driver in the health and wellbeing of European citizens, but many factors have affected its development including consumer safety concerns, strong environmental movements and little social acceptance. The EC’s Eurobarometer survey, however, showed that 80% of Europeans are in favor of, or unopposed to, biotechnology, although there is still a demand for more facts and communication.
Overall, there was great support for medical biotechnology, with 68% of respondents approving of stem cell research and 63% approving of embryonic stem cell research. Additionally, 58% of respondents approve of xenotransplantation, which is subject to moratoria in a number of countries. The support for medical biotechnology also reaches to non-therapeutic applications, with 56% of respondents approving of research aiming to enhance human performance. However, there was also a strong consensus that strict laws will be needed to alleviate concerns about ethical issues.
Biobanks were also well supported. Although only one in three respondents had heard about biobanks, nearly one in two said they would definitely or probably participate in them, with Scandinavian countries showing particularly enthusiasm.
“These findings are very encouraging,” Nathalie Moll, Secretary General at the European Association for Bioindustries (EuropaBio), said in a press statement. “They show that Europeans increasingly understand and appreciate the benefits that biotechnology brings... In particular, we are delighted by the overwhelming support for medical biotechnology and for the strong support shown for crop-based and non-food based biofuels.”
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.